Latham John A 4

4 · ALDER BIOPHARMACEUTICALS INC · Filed Nov 5, 2018

Form 4

Period: 2018-11-01

Chief Scientific Officer

Transactions

Exercise/Conversion
Common Stock
2018-11-01$6.76/sh+6,821$46,144→ 250,514 total
Exercise/Conversion
Stock Option (Right to Buy)
2018-11-01−18,181→ 0 total
Exercise: $10.00Exp: 2024-05-06→ Common Stock (18,181 underlying)
Exercise/Conversion
Common Stock
2018-11-01$10.00/sh+18,181$181,810→ 268,695 total
Sale
Common Stock
2018-11-01$13.40/sh−23,683$317,419→ 245,012 total
Sale
Common Stock
2018-11-01$13.78/sh−1,319$18,170→ 243,693 total
Exercise/Conversion
Stock Option (Right to Buy)
2018-11-01−6,821→ 0 total
Exercise: $6.76Exp: 2024-02-10→ Common Stock (6,821 underlying)

Footnotes (5)

[F1]The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018.
[F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.77 to $13.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4.
[F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.77 to $13.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 4 to this Form 4.
[F5]The shares subject to this stock option are fully vested.

Documents

1 file